Grünenthal GmbH clinical trials

The registry lists 92 studies whose lead sponsor is Grünenthal GmbH or one of 5 companies grouped under it. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 21, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 92. Browse all 92 →

• A Clinical Trial of GRT7040 in Adults With Acute Pain Following BunionectomyNot yet recruitingNCT07807644Phase 2
• A First-in-human Trial of GRT7041 in Healthy ParticipantsRecruitingNCT07289776Phase 1
• Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After SurgeryCompletedNCT04967664Phase 3

  Sponsor listed in the registry: Averitas Pharma, Inc. · First submitted after Averitas Pharma, Inc. became part of Grünenthal GmbH

• A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male ParticipantsCompletedNCT07347548Phase 1
• Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]GRT6019CompletedNCT07479745Phase 1
• Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral NeuropathyActive, not recruitingNCT06495424

  Sponsor listed in the registry: Averitas Pharma, Inc. · First submitted after Averitas Pharma, Inc. became part of Grünenthal GmbH

• Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee OsteoarthritisCompletedNCT05248386Phase 3
• Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the KneeCompletedNCT05449132Phase 3
• Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the KneeCompletedNCT05377489Phase 3
• A Trial to Investigate Safety and Pharmacokinetics of GRT6019, Including Food Effect, in Healthy Male ParticipantsCompletedNCT07317063Phase 1
• A Study With Lido-Patch and Placebo Plaster in Patients Suffering From Postherpetic Neuralgia (PHN)CompletedNCT03745404Phase 3
• A Study With Lidocaine 5% Medicated Plaster in Patients Suffering From Postherpetic NeuralgiaCompletedNCT03765697Phase 3
• Naloxegol US PMR CV Safety.Active, not recruitingNCT02813356

  Sponsor listed in the registry: Valinor Pharma LLC · First submitted before Valinor Pharma LLC became part of Grünenthal GmbH

• Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference ProductCompletedNCT05282940Phase 1

  Sponsor listed in the registry: Laboratorios Andromaco S.A. · First submitted after Laboratorios Andromaco S.A. became part of Grünenthal GmbH

• Bioavailability of Eszopiclone 3.0 mg With Regards to Reference ProductCompletedNCT05349396Phase 1

  Sponsor listed in the registry: Laboratorios Andromaco S.A. · First submitted after Laboratorios Andromaco S.A. became part of Grünenthal GmbH

• Bioavailability of Estradiol Valerate and Dienogest 2 mg/2 mg With Regards to Reference ProductCompletedNCT05332106Phase 1

  Sponsor listed in the registry: Laboratorios Andromaco S.A. · First submitted after Laboratorios Andromaco S.A. became part of Grünenthal GmbH

• Bioavailability of Levodopa 250 mg and Carbidopa 25 mg With Regards to Reference ProductCompletedNCT05250141Phase 1

  Sponsor listed in the registry: Laboratorios Andromaco S.A. · First submitted after Laboratorios Andromaco S.A. became part of Grünenthal GmbH

• Bioavailability of Diosmin/Hesperidin (90/10) 500 mg Tablets With Regards to Reference ProductCompletedNCT05158192Phase 1

  Sponsor listed in the registry: Laboratorios Andromaco S.A. · First submitted after Laboratorios Andromaco S.A. became part of Grünenthal GmbH

• Bioavailability of Oseltamivir Phosphate 75 mg With Regards to Reference ProductCompletedNCT05083325Phase 1

  Sponsor listed in the registry: Laboratorios Andromaco S.A. · First submitted after Laboratorios Andromaco S.A. became part of Grünenthal GmbH

• Intra-articular Lopain (MTX-071) Phase I/IIa Study in Chronic Osteoarthritic Knee Joint PainCompletedNCT02566564Phase 1
• Bioavailability of Clormadinone/Ethinyl Estradiol Tablets 2 mg/0.02 mg With Regards to Reference ProductCompletedNCT04713904Phase 1

  Sponsor listed in the registry: Laboratorios Andromaco S.A. · First submitted after Laboratorios Andromaco S.A. became part of Grünenthal GmbH

• Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Fasting ConditionsCompletedNCT04723238Phase 1

  Sponsor listed in the registry: Laboratorios Andromaco S.A. · First submitted after Laboratorios Andromaco S.A. became part of Grünenthal GmbH

• Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Feeding ConditionsCompletedNCT04751318Phase 1

  Sponsor listed in the registry: Laboratorios Andromaco S.A. · First submitted after Laboratorios Andromaco S.A. became part of Grünenthal GmbH

• Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference ProductCompletedNCT04230070Phase 1

  Sponsor listed in the registry: Laboratorios Andromaco S.A. · First submitted after Laboratorios Andromaco S.A. became part of Grünenthal GmbH

• Bioavailability of Levonorgestrel/Ethinyl Estradiol Tablets 0.1 mg/0.02 mg With Regards to Reference ProductCompletedNCT04194905Phase 1

  Sponsor listed in the registry: Laboratorios Andromaco S.A. · First submitted after Laboratorios Andromaco S.A. became part of Grünenthal GmbH

• A Clinical Study to Compare MAR-CUTIS With Dermabond AdvancedTerminatedNCT03688880Not applicable
• Efficacy and Safety of Intravenous Neridronic Acid in CRPSTerminatedNCT03530345Phase 3
• Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)TerminatedNCT03560986Phase 3
• Bioavailability of Clotiazepam 5 mg With Regards to Reference ProductCompletedNCT04440423Phase 1

  Sponsor listed in the registry: Laboratorios Andromaco S.A. · First submitted after Laboratorios Andromaco S.A. became part of Grünenthal GmbH

• Bioavailability of Desogestrel 0.075 mg Tablets With Regards to Reference ProductCompletedNCT04422028Phase 1

  Sponsor listed in the registry: Laboratorios Andromaco S.A. · First submitted after Laboratorios Andromaco S.A. became part of Grünenthal GmbH

• A Study to Look at Tapentadol Oral Solution in Children and Adolescents in PainCompletedNCT02081391Phase 3
• Bioavailability of Dienogest 2.0 mg With Regards to Reference ProductCompletedNCT04230083Phase 1

  Sponsor listed in the registry: Laboratorios Andromaco S.A. · First submitted after Laboratorios Andromaco S.A. became part of Grünenthal GmbH

• Bioavailability of Dienogest and Ethinyl Estradiol Tablets 2.0 mg/0.03 mg With Regards to Reference ProductCompletedNCT04193852Phase 1

  Sponsor listed in the registry: Laboratorios Andromaco S.A. · First submitted after Laboratorios Andromaco S.A. became part of Grünenthal GmbH

• Safety of Intravenous Neridronic Acid in CRPSCompletedNCT02972359Phase 3
• A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and MorphineCompletedNCT00472303Phase 3
• Tapentadol in Chronic Malignant Tumour Related PainTerminatedNCT01264887Phase 3
• Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative PainCompletedNCT01729728Phase 2
• A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and MorphineTerminatedNCT00505414Phase 3
• A Study to Assess the Safety and Efficacy of 7 Days Treatment With a Novel Analgesic in Subjects With Peripheral Neuropathic PainTerminatedNCT01485094Phase 2
• Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and PregabalinCompletedNCT01352741Phase 4
• A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal HysterectomyCompletedNCT00478023Phase 3
• A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983YTerminatedNCT01056315Phase 2
• Intravenous Tapentadol in Post-Bunionectomy PainCompletedNCT01435577Phase 2
• Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular AnalgesicCompletedNCT00983073Phase 3
• Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability.TerminatedNCT00982280Phase 3
• A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the KneeCompletedNCT00486811Phase 3
• Lidocaine 5% Medicated Plaster in Chronic Neuropathic Postoperative PainTerminatedNCT01155986Phase 2
• Efficacy and Safety of Topical Versus Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic PainCompletedNCT00414349Phase 3
• A Study to Look at Tapentadol Tablets in Children and Adolescents in PainCompletedNCT02151682Phase 2/3
• Tramadol/Diclofenac Fixed-dose Combination Phase III Trial in Acute Pain After Third Molar ExtractionCompletedNCT03714672Phase 3